Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of “Hold” by Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned a consensus rating of “Hold” from the seventeen ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $28.70.

Several brokerages have recently weighed in on HIMS. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Needham & Company LLC raised their price target on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Bank of America cut their price objective on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, May 26th. Finally, Canaccord Genuity Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, May 12th.

Insider Buying and Selling

In related news, Director David B. Wells acquired 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was bought at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the acquisition, the director owned 224,417 shares in the company, valued at $5,437,623.91. This represents a 27.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 7,950 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at approximately $6,216,232.56. The trade was a 2.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Bank of America Corp DE boosted its holdings in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares during the last quarter. Norges Bank acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $62,153,000. Invesco Ltd. boosted its holdings in shares of Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares during the last quarter. Finally, Clear Street Group Inc. acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $87,372,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $26.12 on Monday. The stock has a market capitalization of $6.05 billion, a P/E ratio of -290.22, a P/E/G ratio of 50.75 and a beta of 2.37. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a 50 day moving average of $24.08 and a 200-day moving average of $27.38. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.20 earnings per share. As a group, equities research analysts forecast that Hims & Hers Health will post 0.04 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.